Asia

Shionogi, Inc.: Deanne Melloy, Executive Vice President and Chief Operating Officer

When Shionogi Inc., was first established in the United States a little over a year ago by its Japanese parent company, Shionogi & Co. Ltd., it had the benefit of an 11-year presence in the U.S. marketplace. However, that presence didn’t actually become commercial until a recent acquisition. As Deanne Melloy, executive vice president and […]

VN:F [1.9.7_1111]
Rating: 0 (from 0 votes)
0 comments Read the full article →

PRA: Kent Thoelke, Executive Vice President of Scientific and Medical Affairs

Clinical trial accrual in the United States runs around 3 percent and often takes a “keep your fingers crossed” approach. Up to the point of beginning clinical trials, drug development follows detailed research and design processes steeped in scientific methodology. One contract research organization (CRO) is working to change the landscape of clinical-trial design and […]

VN:F [1.9.7_1111]
Rating: 0 (from 0 votes)
0 comments Read the full article →

Advocates say FDA guidelines far too lax

For those who don’t know how the agency works, the following may come as a surprise, but it’s indeed the way the FDA does business.  While most state and federal agencies rely on regulations, and in most cases get really nasty when those regs aren’t followed, the FDA issues “guidance.” We’re talking voluntary guidance, not […]

VN:R_U [1.9.7_1111]
Rating: +4 (from 4 votes)
0 comments Read the full article →

Is healthcare ripe for a new M&A boom?

With a well defined need in the air– in this case, integration of clinical systems  and personnel — and uncertainty as to how the job will get done,  expect to see waves of self-protective healthcare merger and acquisition activity in the near term. According to Mark Reibolt, CPA, managing partner and chief executive officer of […]

VN:R_U [1.9.7_1111]
Rating: +2 (from 2 votes)
0 comments Read the full article →

China to drive growth of global pharma in ’11

China

Recently, we reported that China was popular with investors looking to build new hospital empires or engage in M&A. That includes China Healthcare Corp., an ambitious venture backed by Frist money, as in Frist of giant hospital chain HCA. While it’s a bureaucratic  nightmare to get permission to build or operate there — or so we’ve […]

VN:F [1.9.7_1111]
Rating: +2 (from 2 votes)
0 comments Read the full article →